LUX Infusion, a US-based clinician-led infusion service network, announced it is now authorised to dispense Qfitlia (fitusiran), expanding access to hemophilia treatment. The subcutaneous therapy is for patients aged 12 and older with hemophilia A or B, with or without Factor VIII or IX inhibitors, requiring routine bleed prevention treatment. The company provides comprehensive support throughout the treatment process, including benefit navigation and 24/7 on-call guidance. LUX Infusion pairs each patient with a dedicated contact who has bleeding disorder experience and works closely with Hemophilia Treatment Centers. "Adding Qfitlia to our portfolio enables us to offer a unique treatment option that is fully supported by our high-touch model," said Ted Kramm, chief executive officer of LUX Infusion.

Specialty Pharmacy news roundup: august 2026. The following are just a few of the many recent specialty pharmacy activities during the past month. Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene, and rare disease therapies, has been selected by Cycle Pharmaceuticals as a limited distribution specialty pharmacy provider for CAVHANZA (nilotinib) Orally Disintegrating Tablets. CAVHANZA is a tyrosine kinase inhibitor indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase; and/or adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. Biologics by McKesson has also been selected by Revolution Medicines as a specialty pharmacy provider for RASONQUE (daraxonrasib) within its distribution network. RASONQUE is an oral therapy approved for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. Carepoint Pharmacy, an end-to-end access hub and dispensing pharmacy serving patients nationwide, announced a new partnership with and investment from New Heritage Capital, a Boston-based private equity firm focused on partnering with high-growth, founder-owned businesses. The investment was structured using Heritage's Private IPO solution, which leaves operating control in the hands of current Carepoint management while providing the financial flexibility to accelerate future growth. LUX Infusion, a clinician-led infusion services company, announced the acquisition of Infuse IQ, a trusted Wyoming-headquartered independent infusion therapy provider delivering safe, personalized infusion and injection treatments across a broad range of medical specialties. The acquisition expands LUX Infusion's ambulatory infusion network and strengthens its ability to serve patients and referring providers in communities across the country. Onco360, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Rigel Pharmaceuticals for VEPPANU (vepdegestrant), which is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Onco360 has also been selected as a pharmacy partner by Revolution Medicines for RASONQUE (daraxonrasib), which is an inhibitor of the RAS GTPase family, indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. PANTHERx Rare has been selected by Intercept Pharmaceuticals, Inc., a wholly owned subsidiary of Alfasigma S.p.A., as the exclusive U.S. specialty pharmacy partner to distribute LYNAVOY (linerixibat), the first FDA-approved treatment specifically indicated for cholestatic pruritus in adults with primary biliary cholangitis (PBC). This collaboration underscores the company's commitment to innovative rare disease care and its mission to reduce barriers for patients facing complex conditions. PANTHERx Rare has also been selected by Vera Therapeutics, Inc. to dispense TRUTAKNA (atacicept-vymj), an FDA-approved treatment indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. IgAN is a complex, progressive kidney disease, and timely access to treatment can make a meaningful difference. The company's team is committed to helping patients navigate access, stay on therapy, and receive personalized support every step of the way. You can find even more news and insights by subscribing to AMI's Specialty Pharmacy Database. Keep up with accreditations earned, key decision-maker changes, mergers and acquisitions and MORE.

/PRNewswire/ -- LUX Infusion, a clinician-led infusion services company, today announced the acquisition of Infuse IQ, a trusted Wyoming-headquartered...